Research location
Hilversum
Netherlands
Advertisement
Research activity in Hilversum
NetherlandsCureCurrent currently publishes aggregate city-level research activity for this location: 77 trials and 77 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Hilversum
77 linked trials · page 1 of 2Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · 2025-12-18 · 1 site observation
RECRUITING
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation
RECRUITING
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's DiseaseNCT07680335 · 2025-09-17 · 1 site observation
RECRUITING
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07164443 · 2025-09-02 · 1 site observation
RECRUITING
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation
RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating LymphocytesNCT06476119 · 2025-04-15 · 1 site observation
RECRUITING
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureNCT06742723 · 2025-03-03 · 1 site observation
RECRUITING
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaNCT06220032 · 2024-08-15 · 1 site observation
RECRUITING
Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate CancerNCT07260435 · 2024-02-20 · 1 site observation
RECRUITING
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 1 site observation
RECRUITING
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast CancerNCT04486495 · 2020-07-16 · 1 site observation
RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.NCT06268873 · 2024-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Dual Hormone Closed Loop in Type 1 DiabetesNCT05669547 · 2023-10-03 · 1 site observation
COMPLETED
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKDNCT05374291 · 2022-11-08 · 1 site observation
ENROLLING_BY_INVITATION
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTENCT05171049 · 2022-05-05 · 1 site observation
TERMINATED
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)NCT04509674 · 2020-12-16 · 1 site observation
COMPLETED
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)NCT04497844 · 2020-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%NCT04435626 · 2020-09-14 · 1 site observation
COMPLETED
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyNCT04493853 · 2020-07-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseaseNCT03819153 · 2019-06-17 · 1 site observation
COMPLETED
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.NCT03283384 · 2019-06-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With MalignancyNCT04657120 · 2019-06-01 · 1 site observation
COMPLETED
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 StudyNCT03820063 · 2019-02-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerNCT03732820 · 2018-10-31 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test Radium-223 With Docetaxel in Patients With Prostate CancerNCT03574571 · 2018-06-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Pharmacogenetics Use For Further Treatment Improvement in childreNNCT03654508 · 2018-06-12 · 1 site observation
COMPLETED
Effect and Feasibility of Non-linear Periodized Resistance Training in People With COPDNCT03518723 · 2018-04-16 · 1 site observation
COMPLETED
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerNCT03425838 · 2017-11-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)NCT03285763 · 2017-10-25 · 1 site observation
COMPLETED
Management of Low-risk (Grade I and II) DCISNCT02492607 · 2017-02-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)NCT02987543 · 2017-02-06 · 1 site observation
COMPLETED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · 2016-11-30 · 1 site observation
COMPLETED
Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung CancerNCT02743923 · 2016-04-01 · 1 site observation
UNKNOWN
LUME BioNIS: a Biomarker Study in Patients With NSCLCNCT02671422 · 2016-03-09 · 1 site observation
COMPLETED
To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid ArthritisNCT02534896 · 2015-11-01 · 1 site observation
TERMINATED
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT02495974 · 2015-09-08 · 1 site observation
COMPLETED
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT02366143 · 2015-03-31 · 1 site observation
COMPLETED
Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a MastectomyNCT02112682 · 2014-06-01 · 1 site observation
TERMINATED
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate CancerNCT02111577 · 2014-05-26 · 1 site observation
COMPLETED
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneNCT02109913 · 2014-03-01 · 1 site observation
UNKNOWN
A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC ParticipantsNCT02040935 · 2014-02-21 · 1 site observation
COMPLETED
PRevention of Macular EDema After Cataract SurgeryNCT01774474 · 2013-07-10 · 1 site observation
COMPLETED
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast CancerNCT01898117 · 2013-07-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)NCT01715285 · 2013-02-12 · 1 site observation
COMPLETED
U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)NCT01918267 · 2012-04-10 · 1 site observation
COMPLETED
Testing the Developmental Origins HypothesisNCT01545492 · 2012-01-01 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.